论文部分内容阅读
目的:探讨活血通络方联合阿卡波糖片治疗高血压病合并高血糖的临床疗效。方法:根据2007年ADA推荐的糖尿病诊断标准选取352例病例并分为空腹血糖调节受损(IFG)190例、糖耐量减低(IGT)120例、空腹血糖受损合并糖耐量减低(IFG/IGT)42例。所有病例均在降压基础上口服阿卡波糖片50 mg/次,tid,加服活血通络方水煎剂,每日一剂分2次服,6个月为1个疗程。结果:各组采用联合治疗6个月后,IFG组收缩压、舒张压、空腹血糖及2 h PG均有所下降,与治疗前对比,差异无统计学意义。IFG/IGT组及IGT组治疗后收缩压、2 h PG与治疗前对比,差异显著(P<0.05),而舒张压和空腹血糖虽有改善,但与治疗前比无统计学差异。具有良好的药物安全性、耐受性。结论:活血通络方联合阿卡波糖片治疗高血压合并IGF以及高血压合并IFG/IGT,可降低患者收缩压和24 h PG,用于高血压合并高血糖患者的干预治疗。
Objective: To investigate the clinical efficacy of Huoxuetongluo combined with acarbose in treating hypertension complicated with hyperglycemia. Methods: According to the diagnostic criteria of ADA in 2007, 352 cases were selected and divided into 190 cases of impaired fasting glucose regulation (IFG), 120 cases of impaired glucose tolerance (IGT), impaired fasting glucose and impaired glucose tolerance (IFG / IGT ) 42 cases. All cases were based on oral anti-acarbapram 50 mg / time, tid, plus serving Huoxuetongluo Decoction, daily dose of 2 times service, 6 months for a course of treatment. Results: The systolic blood pressure, diastolic blood pressure, fasting blood glucose and 2 h PG in IFG group decreased after 6 months of combination treatment. There was no significant difference between before and after treatment in each group. Systolic blood pressure was significantly lower in IFG / IGT group and IGT group than that before treatment (P <0.05), while diastolic blood pressure and fasting blood glucose were significantly improved at 2 h PG compared with before treatment, but there was no significant difference between before and after treatment. Has good drug safety, tolerance. CONCLUSION: Huoxuetongluo combined with acarbose can reduce the systolic blood pressure and 24 h PG in patients with hypertension and hyperglycemia when treated with hypertension combined with IGF and hypertension with IFG / IGT.